New malaria vaccine combo shows promise in early trial
NCT ID NCT06507605
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial tested a new malaria vaccine that combines two different vaccine components (Pfs230D1 and R21) with an immune-boosting adjuvant called Matrix-M. The study involved 240 healthy adults aged 18 to 50 in Africa. The main goal was to check the vaccine's safety and how well it triggers an immune response, with the hope of eventually preventing both malaria infection and its spread.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Malaria vaccine (Pfs230D1 and R21 combination with Matrix-M adjuvant)
- What this could lead to
- If successful, this could lead to a more effective malaria vaccine that blocks both infection and transmission.
- What could go wrong
- This is an early Phase 1 trial focused on safety, not yet on preventing malaria. The vaccine may not produce strong enough immunity or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREVENTION OF MALARIA TRANSMISSION AND CLINICAL MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Science, Technique and Technology of Bamako (Usttb)
Bamako, Mali
More trials for these conditions
Other studies related to the condition(s) this trial covers.